- PDUFA target action date of May 8, 2027 - If approved, encaleret will be the first and only approved therapy specifically indicated for individuals living with ADH1, representing a potential blockbuster opportunity for BridgeBio- Encaleret demonstrated consistent efficacy across all pre-specified primary and key secondary efficacy endpoints normalizing key markers of CaSR-driven disease biologywithout the need for calcium and vitamin D supplements, with a favorable safety and tolerability prof

Financing will support development of RN-014 and RN-032 and continued expansion of the company's kidney disease pipeline July 21, 2026 -- Rege Nephro Co., Ltd. ("Rege Nephro"), a clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, today announced the closing of a financing round totaling approximately US$10.6 million through the issuance of J-KISS (Japan-Keep It Simple Security) share acquisition rights. The proceeds are expected to su

July 20, 2026 -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been dosed in a Phase II clinical study (AK146D1-201) evaluating its internally developed TROP2/Nectin-4 bispecific antibody-drug conjugate (ADC), AK146D1, in combination with ivonescimab (the Company's PD-1/VEGF bispecific antibody) in patients with advanced non-small cell lung cancer (NSCLC). The study will explore the therapeutic potential of this combination, with a particular emphasi

IM-3050 is a fibroblast activation protein (FAP)-targeted radioligand therapy designed to deliver radioactive lutetium-177 directly to FAP-expressing cells. The Phase 1 trial is designed to evaluate the safety, tolerability, dosimetry, pharmacokinetics, and preliminary anti-tumor activity of IM-3050 in participants with FAP-expressing advanced solid tumors. Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies,

This Tamgiblimab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

This Sotevtamab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

This Lesabelimab Biologics Sequence Review Report was produced with PatSnap Biology Modality MCP workflows. It connects patent-scale similarity search, sequence retrieval, pairwise alignment and antibody–antigen evidence in a reproducible screen. Explore the PatSnap MCP servers used in this report. Review date: 23 July 2026. This report supports R&D and IP triage; it is not a legal opinion, freedom-to-operate conclusion or validity analysis. A sequence hit does not establish infringement.

Proceeds will be used to advance the company's AI-native cardiovascular platform and expand partnerships with health plans and cardiology practices nationwide July 21, 2026 -- Karoo Health, a cardiovascular technology company building an operating system supporting cardiac care, today announced the closing of a $16.2 million Series A financing round co-led by 7wire Ventures and Allumia Ventures, with participation from First Trust Capital Partners, LLC, SpringRock Ventures, Hyde Park Angels (HP

Dimerix acquires Phase 2-ready asset, DMX-652 - with potential for rapid advancement into a Phase 2 clinical study under an open US Investigational New Drug (IND) application, with initial focus on acute kidney injury (AKI) DMX-652 offers potential to address a significant unmet need in AKI - with a global market opportunity estimated to be US$3.5 billion in 2026,[1] and no currently approved therapies for the disease which is associated with rapid decline in kidney function and high mortality r

Three-year data from phase 2 trial will provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response Data will also offer insight into the vaccine’s effect also as stand-alone treatment of patients with advanced melanoma Unprecedented two-year data from the trial presented last year showed high response rates and an impressive durability of responses July 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio